SCHEMBL3506070

SCHEMBL3506070

CCN1CCc2cc(OC)c(O)cc2C1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.67
CA9 Q16790 1/20 0.67
DHCR7 Q9UBM7 3/20 0.63
KDM4E B2RXH2 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 1/20 0.58
ABCB1 P08183 3/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
ABCC1 P33527 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
DRD3 P35462 4/20 0.53
DRD4 P21917 3/20 0.53
DRD2 P14416 4/20 0.52
DRD1 P21728 1/20 0.52
DRD5 P21918 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6369583 0.89 ABCB1 (0.69) KDM4ETDP1GAAMAPTRAB9A
SCHEMBL3505441 0.88 DHCR7 (0.70) CA2CA9DHCR7KDM4ETDP1
SCHEMBL13249664 0.86 ABCB1 (0.75) CA2CA9DHCR7KDM4ETDP1
SCHEMBL6369684 0.85 CA2 (0.48) CA2CA9DHCR7KDM4ETDP1
Hydrochloric Acid SCHEMBL3509028 0.85 ABCB1 (0.73) CA2CA9DHCR7KDM4ETDP1
SCHEMBL14739822 0.84 ABCB1 (0.80) CA2CA9DHCR7KDM4EGAA
SCHEMBL14739726 0.84 ABCB1 (0.80) CA2CA9DHCR7KDM4EGAA
SCHEMBL14739918 0.84 ABCB1 (0.80) CA2CA9DHCR7KDM4EGAA
SCHEMBL25947932 0.83 ABCB1 (0.58) CA2CA9KDM4ETDP1GAA
SCHEMBL6370878 0.83 ABCB1 (0.58) CA2CA9KDM4ETDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173672-B2 Quinolizidinone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2012-05-08 US disclosed
US-20110046145-A1 Quinolizidinone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME CORP. (US) 2011-02-24 US disclosed
US-20100217003-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2010-08-26 US disclosed
US-20100217003-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2010-08-26 US disclosed
EP-2117547-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES University Of Ulsan Foundation For Industry Cooperation (KR) 2009-11-18 EP disclosed
WO-2008069632-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046145-A1 Quinolizidinone M1 Receptor Positive Allosteric Modulators CHRM1, CHRM2, OPRL1 CA2 3273/4885CA9 4588/4885DHCR7 2311/4885
US-20100217003-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES NFKBIA, HMOX1, PTGS1 CA2 3608/4885CA9 4751/4885DHCR7 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.